Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 6/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARD | Q03181 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194236 | 1.00 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL6135534 | 1.00 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| Zinc Ion SCHEMBL9731009 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL9679131 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL10731314 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| Zinc Ion SCHEMBL10726528 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| Zinc Ion SCHEMBL9704026 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL9679116 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL10732351 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD | |
| SCHEMBL11860350 | 0.96 | FABP3 (0.50) | FABP3CES2CES1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107106568-B | Pharmaceutical compositions of fused aminodihydrothiazine derivatives | 卫材R&D管理有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-3205343-B1 | PHARMACEUTICAL COMPOSITION OF FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-10117876-B2 | Pharmaceutical composition of fused aminodihydrothiazine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-11-06 | — | — | US | disclosed |
| US-20180263998-A1 | PHARMACEUTICAL COMPOSITION OF FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-10076524-B1 | — | — | 2018-09-18 | — | — | US | disclosed |
| EP-3205343-A1 | PHARMACEUTICAL COMPOSITION OF FUSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2017-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076524-B1 | — | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, SLC10A1 | FABP3 981/4885CES2 1336/4885CES1 1095/4885 |
| US-20180263998-A1 | PHARMACEUTICAL COMPOSITION OF FUSED AMINODIHYDROTHIAZINE DERIVATIVE | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP7A1 | FABP3 2560/4885CES2 2671/4885CES1 2097/4885 |
| US-10117876-B2 | Pharmaceutical composition of fused aminodihydrothiazine derivative | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP7A1 | FABP3 2560/4885CES2 2671/4885CES1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.